Latest news with #VandaPharmaceuticals
Yahoo
17-05-2025
- Business
- Yahoo
Vanda Pharmaceuticals Announces Participation in the Mizuho Neuro & Ophthalmology Summit 2025
WASHINGTON, May 16, 2025 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced that the company will participate in investor meetings at the Mizuho Neuro & Ophthalmology Summit 2025 in New York City on Wednesday, May 21, 2025. About Vanda Pharmaceuticals Inc. Vanda is a leading global biopharmaceutical company focused on the development and commercialization of innovative therapies to address high unmet medical needs and improve the lives of patients. For more on Vanda Pharmaceuticals Inc., please visit and follow us on X @vandapharma. Corporate Contact:Kevin MoranSenior Vice President, Chief Financial Officer and Treasurer Vanda Pharmaceuticals Inc.202-734-3400pr@ Jim Golden / Jack Kelleher / Dan Moore Collected Strategies VANDA-CS@ View original content to download multimedia: SOURCE Vanda Pharmaceuticals Inc.
Globe and Mail
10-04-2025
- Business
- Globe and Mail
Vernal Keratoconjunctivitis Clinical Trials and Studies 2025: EMA, PDMA, FDA Approvals, Mechanism of Action, ROA, NDA, IND, and Companies
DelveInsight's, 'Vernal Keratoconjunctivitis Pipeline Insight 2025' report provides comprehensive insights about 5+ companies and 5+ pipeline drugs in Vernal Keratoconjunctivitis pipeline landscape. It covers the Vernal Keratoconjunctivitis pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Vernal Keratoconjunctivitis therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. Discover the latest drugs and treatment options in the Vernal Keratoconjunctivitis Pipeline. Dive into DelveInsight's comprehensive report today! @ Vernal Keratoconjunctivitis Pipeline Outlook Key Takeaways from the Vernal Keratoconjunctivitis Pipeline Report DelveInsight's Vernal Keratoconjunctivitis pipeline report depicts a robust space with 5+ active players working to develop 5+ pipeline therapies for Vernal Keratoconjunctivitis treatment. The leading Vernal Keratoconjunctivitis Companies such as iCo Therapeutics, Vanda Pharmaceuticals, Sylentis, Allakos and others. Promising Vernal Keratoconjunctivitis Pipeline Therapies such as Cyclosporine A, Dexamethasone, FK506 and others. Stay ahead with the most recent pipeline outlook for Vernal Keratoconjunctivitis. Get insights into clinical trials, emerging therapies, and leading companies with DelveInsight @ Vernal Keratoconjunctivitis Treatment Drugs Vernal Keratoconjunctivitis Emerging Drugs Profile iCo-008: iCo Therapeutics Bertilimumab is a fully human monoclonal antibody with specificity for human eotaxin-1 and inhibits its function. Favourable results from pre-clinical assessments resulted in three clinical studies of bertilimumab conducted in EU (a total of 126 patients – healthy individuals, patients with a history of seasonal allergic rhinitis and individuals with a history of seasonal allergic conjunctivitis) provided evidence of good safety and tolerability of bertilimumab when administered by the intravenous (IV) or intranasal route as well as topical application to the eye. A Phase II clinical trial for patients with vernal keratoconjunctivitis and/or atopic keratoconjunctivitis (involving cornea and conjunctiva) is in preparation. The Vernal Keratoconjunctivitis Pipeline Report Provides Insights into The report provides detailed insights about companies that are developing therapies for the treatment of Vernal Keratoconjunctivitis with aggregate therapies developed by each company for the same. It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Vernal Keratoconjunctivitis Treatment. Vernal Keratoconjunctivitis Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects. Vernal Keratoconjunctivitis Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Vernal Keratoconjunctivitis market Explore groundbreaking therapies and clinical trials in the Vernal Keratoconjunctivitis Pipeline. Access DelveInsight's detailed report now! @ New Vernal Keratoconjunctivitis Drugs Vernal Keratoconjunctivitis Companies iCo Therapeutics, Vanda Pharmaceuticals, Sylentis, Allakos and others. Vernal Keratoconjunctivitis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as Oral Parenteral Intravenous Subcutaneous Topical Molecule Type Products have been categorized under various Molecule types such as Monoclonal Antibody Peptides Polymer Small molecule Gene therapy Product Type Unveil the future of Vernal Keratoconjunctivitis Treatment. Learn about new drugs, pipeline developments, and key companies with DelveInsight's expert analysis @ Vernal Keratoconjunctivitis Market Drivers and Barriers Scope of the Vernal Keratoconjunctivitis Pipeline Report Coverage- Global Vernal Keratoconjunctivitis Companies- iCo Therapeutics, Vanda Pharmaceuticals, Sylentis, Allakos and others. Vernal Keratoconjunctivitis Pipeline Therapies- Cyclosporine A, Dexamethasone, FK506 and others. Vernal Keratoconjunctivitis Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination Vernal Keratoconjunctivitis Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III Get the latest on Vernal Keratoconjunctivitis Therapies and clinical trials. Download DelveInsight's in-depth pipeline report today! @ Vernal Keratoconjunctivitis Companies, Key Products and Unmet Needs Table of Content Introduction Executive Summary Vernal Keratoconjunctivitis: Overview Pipeline Therapeutics Therapeutic Assessment Late Stage Products (Phase III) Drug Name: Company Name Drug profiles in the detailed report….. Mid Stage Products (Phase II) Co-008: iCo Therapeutics Drug profiles in the detailed report….. Early stage products (Phase I) AK002: Allakos Drug profiles in the detailed report….. Inactive Products Vernal Keratoconjunctivitis Key Companies Vernal Keratoconjunctivitis Key Products Vernal Keratoconjunctivitis- Unmet Needs Vernal Keratoconjunctivitis- Market Drivers and Barriers Vernal Keratoconjunctivitis- Future Perspectives and Conclusion Vernal Keratoconjunctivitis Analyst Views Vernal Keratoconjunctivitis Key Companies Appendix About Us DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve. Media Contact Company Name: DelveInsight Business Research LLP Contact Person: Yash Bhardwaj Email: Send Email Phone: 09650213330 Address: 304 S. Jones Blvd #2432 City: Las Vegas State: NV Country: United States Website:
Yahoo
28-02-2025
- Business
- Yahoo
US High Growth Tech Stocks With Strong Potential
Over the last 7 days, the United States market has dropped 4.8%, yet it has risen by 15% over the past year, with earnings anticipated to grow by 14% annually in the coming years. In this context, identifying high growth tech stocks involves looking for companies that demonstrate strong potential through innovation and adaptability to leverage these market dynamics effectively. Name Revenue Growth Earnings Growth Growth Rating Super Micro Computer 25.17% 29.10% ★★★★★★ AsiaFIN Holdings 51.75% 82.69% ★★★★★★ Travere Therapeutics 28.43% 65.01% ★★★★★★ Alkami Technology 21.99% 102.65% ★★★★★★ AVITA Medical 27.78% 55.33% ★★★★★★ TG Therapeutics 29.48% 45.20% ★★★★★★ Bitdeer Technologies Group 44.71% 155.06% ★★★★★★ Clene 61.16% 59.11% ★★★★★★ Alnylam Pharmaceuticals 22.84% 58.60% ★★★★★★ Lumentum Holdings 21.24% 119.37% ★★★★★★ Click here to see the full list of 225 stocks from our US High Growth Tech and AI Stocks screener. Underneath we present a selection of stocks filtered out by our screen. Simply Wall St Growth Rating: ★★★★★☆ Overview: Amicus Therapeutics, Inc. is a biotechnology company dedicated to the discovery, development, and delivery of medicines for rare diseases with a market cap of approximately $2.71 billion. Operations: The company's primary revenue stream, totaling $528.30 million, is derived from the discovery, development, and commercialization of advanced therapies for rare diseases. Amicus Therapeutics, despite its unprofitability, is on a promising trajectory with expected revenue growth of 17.5% annually, outpacing the US market average of 8.7%. The company's recent reduction in net loss from $151.58 million to $56.11 million year-over-year highlights significant financial improvement and operational efficiency. Looking ahead, Amicus anticipates positive GAAP Net Income in the latter half of 2025 and projects revenue increases between 17% to 24%. This forward-looking optimism is supported by robust R&D investments aimed at pioneering treatments in biotechnology, positioning it well within the high-growth tech landscape despite current financial challenges. Unlock comprehensive insights into our analysis of Amicus Therapeutics stock in this health report. Assess Amicus Therapeutics' past performance with our detailed historical performance reports. Simply Wall St Growth Rating: ★★★★★☆ Overview: Vanda Pharmaceuticals Inc. is a biopharmaceutical company dedicated to developing and commercializing therapies for high unmet medical needs globally, with a market cap of $274.67 million. Operations: Vanda Pharmaceuticals focuses on developing and commercializing biopharmaceutical therapies, generating revenue primarily from its biotechnology segment with $198.77 million. Vanda Pharmaceuticals, amidst a challenging regulatory landscape, continues to innovate in the treatment of rare diseases. The company's recent development of VCA-894A, an antisense oligonucleotide for Charcot-Marie-Tooth disease type 2S, underscores its commitment to precision medicine—a field gaining traction within high-growth tech sectors. Despite reporting a widening net loss in Q4 2024 to $4.91 million from $2.4 million the previous year, Vanda projects significant future revenue growth; it anticipates exceeding $1 billion by 2030 with potential approvals on the horizon for Bysanti™ across multiple indications. This forward-looking strategy highlights its pivot towards addressing unmet medical needs through targeted therapies and could reshape treatment paradigms in neuropsychiatric and neurological disorders. Delve into the full analysis health report here for a deeper understanding of Vanda Pharmaceuticals. Learn about Vanda Pharmaceuticals' historical performance. Simply Wall St Growth Rating: ★★★★☆☆ Overview: Kiniksa Pharmaceuticals International, plc is a biopharmaceutical company dedicated to discovering, acquiring, developing, and commercializing therapeutic medicines for patients with debilitating diseases that have significant unmet medical needs globally, with a market cap of approximately $1.43 billion. Operations: Kiniksa Pharmaceuticals generates revenue primarily from developing and delivering therapeutic medicines, totaling $423.24 million. The company focuses on addressing significant unmet medical needs in debilitating diseases worldwide. Kiniksa Pharmaceuticals International, despite a challenging year with a net loss of $43.19 million, is positioning itself for recovery and growth with strategic product developments. In 2024, the company's revenue surged to $423.24 million from $270.26 million the previous year, marking a significant 56% increase. This growth trajectory is supported by innovations such as KPL-387 for recurrent pericarditis and an expected profitable turn within three years. With annual earnings projected to grow by 46.45%, Kiniksa continues to prioritize unmet medical needs in cardiovascular indications, potentially reshaping treatment paradigms and enhancing its market position in high-growth biotech sectors. Dive into the specifics of Kiniksa Pharmaceuticals International here with our thorough health report. Evaluate Kiniksa Pharmaceuticals International's historical performance by accessing our past performance report. Take a closer look at our US High Growth Tech and AI Stocks list of 225 companies by clicking here. Are these companies part of your investment strategy? Use Simply Wall St to consolidate your holdings into a portfolio and gain insights with our comprehensive analysis tools. Elevate your portfolio with Simply Wall St, the ultimate app for investors seeking global market coverage. Explore high-performing small cap companies that haven't yet garnered significant analyst attention. Fuel your portfolio with companies showing strong growth potential, backed by optimistic outlooks both from analysts and management. Find companies with promising cash flow potential yet trading below their fair value. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Companies discussed in this article include NasdaqGM:FOLD NasdaqGM:VNDA and NasdaqGS:KNSA. Have feedback on this article? Concerned about the content? with us directly. Alternatively, email editorial-team@ Sign in to access your portfolio
Yahoo
27-02-2025
- Business
- Yahoo
February 2025 Penny Stocks To Keep An Eye On
As February 2025 unfolds, the U.S. stock market has shown signs of resilience with the S&P 500 and Nasdaq Composite inching higher after a four-day losing streak, despite ongoing concerns about the economic outlook. In this context, penny stocks—often representing smaller or newer companies—continue to capture investor interest due to their affordability and potential for growth. While traditionally viewed with caution, these stocks can offer unique opportunities when backed by strong financials and solid fundamentals. Name Share Price Market Cap Financial Health Rating QuantaSing Group (NasdaqGM:QSG) $3.08 $128.29M ★★★★★★ TETRA Technologies (NYSE:TTI) $3.93 $540.42M ★★★★☆☆ Safe Bulkers (NYSE:SB) $3.89 $410.67M ★★★★☆☆ BAB (OTCPK:BABB) $0.8206 $6.54M ★★★★★☆ Golden Growers Cooperative (OTCPK:GGRO.U) $4.50 $67.38M ★★★★★★ North European Oil Royalty Trust (NYSE:NRT) $4.41 $41.82M ★★★★★★ Permianville Royalty Trust (NYSE:PVL) $1.43 $47.52M ★★★★★★ PHX Minerals (NYSE:PHX) $4.16 $154.05M ★★★★★☆ Smith Micro Software (NasdaqCM:SMSI) $1.35 $23.41M ★★★★★☆ CBAK Energy Technology (NasdaqCM:CBAT) $0.8354 $74.1M ★★★★★☆ Click here to see the full list of 732 stocks from our US Penny Stocks screener. Underneath we present a selection of stocks filtered out by our screen. Simply Wall St Financial Health Rating: ★★★★★★ Overview: Vanda Pharmaceuticals Inc. is a biopharmaceutical company dedicated to developing and commercializing therapies for high unmet medical needs globally, with a market cap of approximately $260.09 million. Operations: The company generates revenue primarily from its biotechnology startup segment, totaling $198.77 million. Market Cap: $260.09M Vanda Pharmaceuticals, with a market cap of US$260.09 million, is trading significantly below its estimated fair value and maintains a debt-free balance sheet with short-term assets exceeding liabilities. Despite being unprofitable and experiencing increased losses over five years, it has not diluted shareholders recently. The company reported Q4 2024 revenue of US$53.19 million but faced challenges such as FDA rejection of its tradipitant NDA for gastroparesis treatment, which Vanda disputes legally. Notably, Vanda's innovative ASO therapeutic for Charcot-Marie-Tooth disease highlights potential advancements in precision medicine for rare diseases. Click here to discover the nuances of Vanda Pharmaceuticals with our detailed analytical financial health report. Review our growth performance report to gain insights into Vanda Pharmaceuticals' future. Simply Wall St Financial Health Rating: ★★★★☆☆ Overview: ATRenew Inc. operates a platform for pre-owned consumer electronics transactions and services in China, with a market cap of approximately $623.33 million. Operations: The company's revenue is derived from its retail electronics segment, generating CN¥15.35 billion. Market Cap: $623.33M ATRenew, with a market cap of US$623.33 million, is unprofitable but has reduced losses by 21.8% annually over the past five years. Its management and board are experienced, boasting tenures of 5.7 and 3.7 years respectively. The company's short-term assets of CN¥4 billion exceed both its short-term liabilities (CN¥1.2 billion) and long-term liabilities (CN¥122.5 million), indicating strong liquidity management despite insufficient data on cash runway sustainability under varying conditions. Debt reduction from 12.3% to 8.5% in five years further strengthens its financial position, while earnings growth is forecasted at a substantial rate of 226%. Unlock comprehensive insights into our analysis of ATRenew stock in this financial health report. Evaluate ATRenew's prospects by accessing our earnings growth report. Simply Wall St Financial Health Rating: ★★★★★★ Overview: Elite Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on developing, manufacturing, and selling oral controlled-release and generic pharmaceuticals with a market cap of $512.77 million. Operations: The company's revenue is primarily generated from Abbreviated New Drug Applications (ANDA), amounting to $70 million. Market Cap: $512.77M Elite Pharmaceuticals, with a market cap of US$512.77 million, is navigating financial challenges despite having short-term assets of US$48 million exceeding both short-term (US$14.7 million) and long-term liabilities (US$39.6 million). The company remains unprofitable but has managed to reduce its losses by 14.5% annually over five years and maintains a cash runway exceeding three years due to positive free cash flow growth. Recent earnings showed revenue of US$52.05 million for the nine months ending December 31, 2024, though net losses reached US$21.31 million compared to a previous net income of US$16.78 million year-over-year. Click here and access our complete financial health analysis report to understand the dynamics of Elite Pharmaceuticals. Review our historical performance report to gain insights into Elite Pharmaceuticals' track record. Access the full spectrum of 732 US Penny Stocks by clicking on this link. Already own these companies? Bring clarity to your investment decisions by linking up your portfolio with Simply Wall St, where you can monitor all the vital signs of your stocks effortlessly. Simply Wall St is a revolutionary app designed for long-term stock investors, it's free and covers every market in the world. Explore high-performing small cap companies that haven't yet garnered significant analyst attention. Jump on the AI train with fast growing tech companies forging a new era of innovation. Find companies with promising cash flow potential yet trading below their fair value. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Companies discussed in this article include NasdaqGM:VNDA NYSE:RERE and OTCPK:ELTP. Have feedback on this article? Concerned about the content? with us directly. Alternatively, email editorial-team@
